CNQX

Cas：115066-14-3 (free acid)

         479347-85-8 (sodium)

Product Information：

CNQX is a water-soluble form of AMPA/kainate antagonist CNQX.

Chemical Formula: C9H2N4Na2O4

Exact Mass: 275.9871

Molecular Weight: 276.11

Elemental Analysis: C, 39.15; H, 0.73; N, 20.29; Na, 16.65; O, 23.18

Synonym: 

CNQX Disodium

CNQX 2Na

Chemical Name:  

sodium 6-cyano-7-nitroquinoxaline-2,3-bis(olate)

InChi Key:

YCXDDPGRZKUGDG-UHFFFAOYSA-L

InChi Code:   InChI=1S/C9H4N4O4.2Na/c10-3-4-1-5-6(2-7(4)13(16)17)12-9(15)8(14)11-5;;/h1-2H,(H,11,14)(H,12,15);;/q;2*+1/p-2

Smiles Code:

N#CC1=C([N+]([O-])=O)C=C2N=C([O-])C([O-])=NC2=C1.[Na+].[Na+]

Technical Data：

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.03.00

In Vitro：

CNQX (FG9065; 2-5 μM) reversibly blocks the Schaffer collateral and mossy fibre excitatory postsynaptic potential (EPSP), while sparing the fast and slow GABA-mediated inhibition in superfusion of hippocampal slices.

CNQX (1-5 μM) produces a selective and dose-dependent reduction in the amplitude of the monosynaptic component of the DR-VRR recorded from lumbar spinal segments.

In Vivo：

CNQX (FG9065; 2-5 μM) reversibly blocks the Schaffer collateral and mossy fibre excitatory postsynaptic potential (EPSP), while sparing the fast and slow GABA-mediated inhibition in superfusion of hippocampal slices.

CNQX (1-5 μM) produces a selective and dose-dependent reduction in the amplitude of the monosynaptic component of the DR-VRR recorded from lumbar spinal segments.

References：

1. Sergeeva OA, De Luca R, Mazur K, Chepkova AN, Haas HL, Bauer A. N-oleoyldopamine modulates activity of midbrain dopaminergic neurons through multiple mechanisms. Neuropharmacology. 2017 Jun;119:111-122. doi: 10.1016/j.neuropharm.2017.04.011. Epub 2017 Apr 9. PubMed PMID: 28400256.

2. Blasiak A, Siwiec M, Grabowiecka A, Blasiak T, Czerw A, Blasiak E, Kania A, Rajfur Z, Lewandowski MH, Gundlach AL. Excitatory orexinergic innervation of rat nucleus incertus--Implications for ascending arousal, motivation and feeding control. Neuropharmacology. 2015 Dec;99:432-47. doi: 10.1016/j.neuropharm.2015.08.014. Epub 2015 Aug 8. PubMed PMID: 26265304.

3. Zagrean AM, Spataru A, CeangaM, Zagrean L. The single versus combinatorial effects of MK-801, CNQX, Nifedipine and AP-3 on primary cultures of cerebellar granule cells in an oxygen-glucose deprivation model. Rom J Morphol Embryol. 2014;55(3):811-6. PubMed PMID: 25329107.

4. Gigout S, Louvel J, Rinaldi D, Martin B, Pumain R. Thalamocortical relationships and network synchronization in a new genetic model "in mirror" for absence epilepsy. Brain Res. 2013 Aug 7;1525:39-52. doi: 10.1016/j.brainres.2013.05.044. Epub 2013 Jun 3. PubMed PMID: 23743261.

5. Ferreira-Neto HC, Yao ST, Antunes VR. Purinergic and glutamatergic interactions in the hypothalamic paraventricular nucleus modulate sympathetic outflow. Purinergic Signal. 2013 Sep;9(3):337-49. doi: 10.1007/s11302-013-9352-9. Epub 2013 Feb 12. PubMed PMID: 23400372; PubMed Central PMCID: PMC3757145.

Products are for research use only. Not for human use.